Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

To view the current issue online, please click here.

Get access to our clinical trials on your iPhone®, iPad® or Android™ mobile devices with the FREE KCI Trials App.

<table>
<thead>
<tr>
<th>Bone Marrow Transplant</th>
<th>Gynecologic</th>
<th>Immunotherapy</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>Head &amp; Neck</td>
<td>Melanoma/Skin</td>
<td>Sarcoma</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Hematology</td>
<td>Neuro-Oncology</td>
<td>Thoracic</td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bone Marrow Clinical Trials

For more information on Bone Marrow Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**BONE MARROW TRANSPLANT**

**STUDY 2015-115**
Phase II
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

**STUDY 2018-084**
Phase I/II
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

**STUDY BMTCTN1506**
Phase III
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.
STUDY 2018-128  
Phase II  
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)

STUDY 2017-081  
Phase III  
Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone versus Lenalidomide Alone after Stem-Cell Transplant for Multiple Myeloma

STUDY 2014-103  
Phase I/II  
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

STUDY 2016-049  
Phase I/II  
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non- Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

STUDY 2011-086  
NA  
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.

IMMUNOTHERAPY

STUDY 2018-008  
Phase III  
A Phase 3, Randomized, Open-Label Study of Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

RETURN TO TOP

Breast Clinical Trials

For more information on Breast Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ADJUVANT

STUDY NRG-BR003  
Phase III  
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

STUDY A011502  
Phase III  
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

STUDY 2017-129  
NA  
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADJUVANT HORMONAL
STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADJUVANT RADIATION
STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

NEoadjuvant
STUDY RTOG1304
Phase III
NSABP B-51 RTOG1304: A Randomized Phase III Clinical Trial Evaluating Post Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.

STUDY S1418
Phase III
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy.

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

ADVANCED (STAGE IV) CHEMOTHERAPY
STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.

STUDY 2018-009
Phase II
A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety and Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2018-054
Phase I
A Phase 1a/1b Study of FPA150, and Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

HORMONAL
STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List.
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016-055</td>
<td>Phase I</td>
<td>A Phase I/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>S1501</td>
<td>Phase III</td>
<td>Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer</td>
</tr>
<tr>
<td>2017-073</td>
<td>Phase II</td>
<td>The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women with Early Stage Breast Cancer</td>
</tr>
<tr>
<td>A011401</td>
<td>Phase III</td>
<td>Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer</td>
</tr>
<tr>
<td>2016-116</td>
<td>Phase II</td>
<td>A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors</td>
</tr>
<tr>
<td>2017-029</td>
<td>Phase I</td>
<td>An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours</td>
</tr>
<tr>
<td>2017-018</td>
<td>Phase I</td>
<td>A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer</td>
</tr>
<tr>
<td>EAY131</td>
<td>Phase II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
<tr>
<td>2018-006</td>
<td>NA</td>
<td>Educational Interventions to Promote Tobacco Cessation Among Women Seeking Mammography Screening</td>
</tr>
<tr>
<td>2018-062</td>
<td>NA</td>
<td>Reducing Metabolic Syndrome and Unmet needs Among Rural Breast Cancer Survivors During the Survivorship Transition</td>
</tr>
<tr>
<td>2018-015</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>2016-037</td>
<td>Phase I</td>
<td>A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
</tbody>
</table>
For more information on Gastrointestinal Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**GASTRIC AND GASTROESOPHAGEAL JUNCTION**

**Metastatic**

**STUDY 2016-210**

Phase I/II

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

**STUDY 2017-150**

Phase I/II

A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

**STUDY 2017-149**

Phase I

A Phase 1/3 Study of FPA144 versus Placebo in Combination with Modified FOLFOX6 in Patients with Previously Untreated Advanced Gastric and Gastroesophageal Cancer

**STUDY NEW 2018-088**

Phase III

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2 Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

**STUDY 2017-029**

Phase I

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

**STUDY 2016-003**

Phase I/II

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

**STUDY 2016-037**

Phase I

A Phase I Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

**STUDY 2018-047**

Phase II

A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Unresectable Gastic or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression

**PANCREAS**

**Adenocarcinoma**

**Locally Advanced Unresectable**

**STUDY 2018-048**

Phase III

PANOVA-3: Pivotal, Randomized, Open-Label Study Of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and nab-Paclitaxel for Font-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma

**Metastatic**

**STUDY 2017-069**

Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-116
Phase II
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2018-090
Phase III
A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

HCC
Adjuvant
STUDY RTOG1112
Phase III
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed By Sorafenib in Hepatocellular Carcinoma

BILIARY/GALL BLADDER
Metastatic
STUDY 2017-101
Phase I/II
A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF-FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

STUDY NEW S1815
Phase III
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and NAB-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

STUDY 2014-081
Phase II
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations who Failed or Are Intolerant to Platinum-Based Chemotherapy

COLON
Adjuvant
STUDY A021502
Phase III
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy of Patients with Stage III Colon Cancer with Deficient DNA Mismatch Repair

Metastatic (Includes Rectal)
1st Line
STUDY NRG-GI004
Phase III
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Metastatic (Includes Rectal)
STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY S1613
Phase II
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

STUDY 2016-185
Phase I/II
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2018-021
Phase II
A Phase 2, Multicenter, Open-Label Study of DS-8201A in Subjects with HER2- Expressing Advanced Colorectal Cancer

STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

RECTUM
STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY EA2165
Phase II
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

ANAL
Metastatic
STUDY EA2165
Phase II
A Randomized PHase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

STUDY 2018-122
Phase II
A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal

NEUROENDOCRINE TUMORS AND CARCINOID
STUDY 2017-144
Pilot
Monitoring Telotristat Ethyl Inhibition of Tryptophan hydroxylase (TPH) in Neuroendocrine Tumors Using alpha-[11C]methyl-L-tryptophan (AMT)-PET

IMAGING STUDIES
Metastatic
STUDY 2018-171
Phase II
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

RETURN TO TOP

Genitourinary Clinical Trials
For more information on Genitourinary Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

RENAL
STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2018-024
Phase II
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

STUDY NEW S1500
Phase II
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

STUDY 2017-082
Phase I/II
A Phase I/II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naïve Metastatic Clear Cell Renal Cell Carcinoma Patients
STUDY 2018-131
Phase II
A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-058
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

STUDY 2016-201
Phase III
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).

STUDY 2017-111
Phase I
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

STUDY 2016-211
Phase II
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY EA8143
Phase III
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2016-055
Phase I
A Phase 1/1b, Open-label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-074
Phase II
A Phase 2, Open Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin-Ineligible Urothelial Cancer

STUDY 2018-018
Phase I/II
An Open Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination with Atezolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

PROSTATE
STUDY 2013-108
NA
Immune Evaluation Study of Sipuleucel-T in African American and Non African American Men with Castrate Resistant Prostate Cancer

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY NRG-GU002
Phase II/III
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

STUDY 2018-124
Phase I/II
Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

STUDY S1802
Phase III
Phase III Randomized Trial of Standard Systemic Therapy (SST) versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.

STUDY NEW 2018-173
Phase III
The MAP TRIAL: Phase III Study of Muscadine Plus (MPX) in Men with Prostate Cancer: A Randomized Double-Blind, Placebo-Controlled Study of the Effects of MPX Capsules on Rising Prostate-Specific Antigen Levels in Alanine/Alanine SOD2 Genotype Men Following Initial Therapy for Prostate Cancer

STUDY 2017-126
Phase II
Phase II Study of Olaparib in Men with High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, with Integrated Biomarker Analysis

STUDY EA8153
Phase II
Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: Phase II the CHAARTED2 Trial

STUDY RTOG0924
Phase III
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

STUDY 2015-135
Phase II
Phase II Trial of Immune Checkpoint Inhibitor with Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer.

STUDY 2017-092
Phase II
<table>
<thead>
<tr>
<th>Study Title</th>
<th>Phase/Design</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy</td>
<td>STUDY 2015-167</td>
<td>Phase II</td>
</tr>
<tr>
<td>A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A Phase IB Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Androgen Deprivation Therapy and Other Agents in Subjects with Castrate Resistant Prostate Cancer (CRPC)</td>
<td>STUDY 2015-029</td>
<td>Phase II</td>
</tr>
<tr>
<td>STUDY 2017-046</td>
<td>Phase I</td>
<td>A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2015-156</td>
<td>Phase II</td>
<td>A Phase II Open-Label, a Miltisite Study of Apalutamide, Abiraterone and Prednisone in African American and Caucasian Men with Metastatic Castrate Resistant Prostate Cancer</td>
</tr>
<tr>
<td>STUDY NRG-GU005</td>
<td>Phase III</td>
<td>Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Rist Prostate Cancer</td>
</tr>
<tr>
<td>A Phase II Open-Label, a Miltisite Study of Apalutamide, Abiraterone and Prednisone in African American and Caucasian Men with Metastatic Castrate Resistant Prostate Cancer</td>
<td>STUDY 2017-129</td>
<td>NA</td>
</tr>
<tr>
<td>Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List</td>
<td></td>
<td>STUDY 2018-015</td>
</tr>
<tr>
<td>A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration Resistant Metastatic Prostate Cancer (CheckMate 9KD: CHECKpoint Pathway and NivoluMAb Clinical Trial Evaluation 9KD)</td>
<td>STUDY 2018-017</td>
<td>Phase II</td>
</tr>
<tr>
<td>An international, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of Lu-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-resistant Prostate Cancer (mCRPC)</td>
<td>STUDY 2018-092</td>
<td>Phase III</td>
</tr>
<tr>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
<td></td>
<td>STUDY 2016-055</td>
</tr>
<tr>
<td>QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin(BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</td>
<td></td>
<td>STUDY 2017-070</td>
</tr>
<tr>
<td>BLADDER</td>
<td></td>
<td>STUDY 2016-195</td>
</tr>
<tr>
<td>Study ID</td>
<td>Phase</td>
<td>Title</td>
</tr>
<tr>
<td>---------------</td>
<td>-------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>STUDY 2018-110</td>
<td>II</td>
<td>A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma</td>
</tr>
<tr>
<td>STUDY 2016-003</td>
<td>I/II</td>
<td>A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors</td>
</tr>
<tr>
<td>STUDY 2017-092</td>
<td>II</td>
<td>A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy</td>
</tr>
<tr>
<td>STUDY 2017-069</td>
<td>I/II</td>
<td>A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors</td>
</tr>
<tr>
<td>STUDY 2017-029</td>
<td>I</td>
<td>An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours</td>
</tr>
<tr>
<td>STUDY NEW 2018-165</td>
<td>I</td>
<td>A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine-Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)</td>
</tr>
<tr>
<td>STUDY 2016-175</td>
<td>II</td>
<td>A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td>I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2018-044</td>
<td>II</td>
<td>Phase 2 Trial of Olaparib in Patients with Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations</td>
</tr>
<tr>
<td>STUDY 2018-015</td>
<td>I/II</td>
<td>A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-101</td>
<td>I/II</td>
<td>A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>I</td>
<td>A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2018-023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study ID</td>
<td>Phase</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>-------</td>
<td>------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>STUDY 2018-098</td>
<td>Phase I</td>
<td>A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors</td>
</tr>
<tr>
<td>OTHER</td>
<td>Phase II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
<tr>
<td>STUDY 2018-171</td>
<td>Phase II</td>
<td>A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PE Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors</td>
</tr>
</tbody>
</table>

**Gynecologic Clinical Trials**

For more information on Gynecologic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

**CERVIX**

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-010</td>
<td>Phase II</td>
<td>A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma</td>
</tr>
<tr>
<td>STUDY 2018-103</td>
<td>Phase III</td>
<td>A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)</td>
</tr>
<tr>
<td>STUDY 2017-069</td>
<td>Phase I/II</td>
<td>A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors</td>
</tr>
</tbody>
</table>

**OVARY**

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase III</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY GOG-3020</td>
<td>ATHENA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy</td>
<td></td>
</tr>
<tr>
<td>STUDY 2018-043</td>
<td>Phase III</td>
<td>A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer</td>
</tr>
</tbody>
</table>
STUDY NEW GOG-3018
Phase III
The OVAL Study: A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

STUDY NEW 2018-159
Phase II
Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2018-054
Phase I
A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Solid Advanced Tumors

STUDY 2018-015
Phase I/I
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy of BI 754091 In Patients With Advanced Solid Tumors

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY NEW NRG-GY012
Phase II
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.

STUDY 2018-054
Phase I
A Phase 1a/1b Study of FPA 150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

Head & Neck Clinical Trials
For more information on Head & Neck Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

STAGES I/II/III
STUDY 2016-093
Phase I/I
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing
AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY EA3132
Phase II
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

STUDY 2017-157
Stage III
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for A Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

STUDY EA3163
Phase II
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

STUDY 2017-042
Phase I/II
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer

STUDY RTOG1008
Phase II/III
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

ANY STAGE
STUDY 2016-212
Phase II
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY 2017-107
Phase III
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942(Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-017
Phase I/II
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-171
Phase II
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2017-101
Phase I/II
A Dose-Finding Pase I Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF-FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

RETURN TO TOP

Hematology Clinical Trials

For more information on Hematology Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpl@karmanos.org or fill out this online referral form.

MULTIPLE MYELOMA

STUDY 2012-122
Phase I/II
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma

STUDY 2016-120
Phase I
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma

STUDY 2016-062
Phase I/II
Phase 1/2 Trial of Idasanutlin in Combination with Ixazomib and Dexamethasone in Patients with 17p Deleted, Relapsed Phase I/II Multiple Myeloma

STUDY 2017-136
Pilot
An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients with Relapsed and/or Refractory Multiple Myeloma

STUDY 2017-151
Phase IV
An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (TOURMALINE US MM-6)

STUDY 2018-014
Phase I
A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

STUDY 2018-028

Phase II
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens

STUDY 2016-086

Phase I
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

STUDY 2017-024

Phase II
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab

STUDY 2018-026

Phase II
A Phase II Study of CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

AMYLOIDOSIS or LIGHT CHAIN DEPOSITION DISEASE

STUDY 2012-066

Phase III
A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

STUDY 2016-200

Phase II
A Randomized Phase 2 Trial of Revlimid/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide followed by Revlimid/ Dexamethasone/Elotuzumab Maintenance as Second-line Therapy for Patients with Relapsed AL Amyloidosis

STUDY S1702

Phase II
A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated Phase II AL Amyloidosis

STUDY 2017-067

Phase III
Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

STUDY 2016-060

Phase I
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123x CD3 DouBody in Subjects with Relapsed or Refractory AML

LEUKEMIA

Acute Lymphoblastic Leukemia (ALL)

STUDY E1910

Phase III
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABLnegative B lineage Acute Lymphoblastic Leukemia in Adults

Acute Myeloid Leukemia (AML)
STUDY BMTCTN1506
Phase III
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY 2018-027
Phase I/II
A Phase I/II, Open-Label, Multicenter 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients Not Eligible for Intensive Induction Therapy

STUDY 2017-119
Phase III
Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects < or = 75 Years of Age with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

STUDY NEW 2015-093
Phase II
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy

STUDY 2017-120
Phase III
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

STUDY 2016-035
Phase I
A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

STUDY 2016-103
Phase I
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Chronic Lymphocytic Leukemia (CLL)
STUDY 2014-132
Phase III
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

STUDY A041702
Phase III
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (greater than or equal to 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Chronic Myeloid Leukemia (CML)
STUDY 2015-128
Phase II
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

LYMPHOMA
Hodgkin's
STUDY 2017-132
Phase II
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2017-100</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td>Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint pathway and nivaluMAb clinical Trial Evaluation 812)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2016-033</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II</td>
<td>A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Hodgkin's Lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-Hodgkin's Aggressive (Mantle Cell, Large B-Cell Lymphoma)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2017-025</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td>Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2013-047</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I</td>
<td>A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2017-125</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td>A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing The Efficacy And Safety Of Polatuzumab Vedotin In Combination With Rituximab And Chp (R-Chp) Versus Rituximab And Chop (R-Chop) In Previously Untreated Patients With Diffuse Large B-Cell Lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY NEW 2018-094</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I/II</td>
<td>An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Mosunetuzumab (Btct4465a) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2015-150</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I/II</td>
<td>A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Polatuzumab Vedotin and Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2018-008</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td>A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloeucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2014-132</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase III</td>
<td>A Phase 3b, Multicenter, Open-Label, PCI-32765 (Ibrutinib) Long-term Extension Study</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>T cell</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2016-210</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase I/II</td>
<td>An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
STUDY 2016-056
Phase II
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

STUDY 2018-003
Phase I
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma

STUDY 2017-008
Phase I
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients with Advanced Tumors and Lymphomas

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

MYELODYSPLASTIC SYNDROME (MDS)
STUDY 2016-035
Phase I
A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Study 2018-027
Phase I/II
A Phase I/II, Open-Label, Multicenter 2-Part Study to Asses the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukemia/High-Risk Myelodysplastic Syndrome or Treatment-Naive Patients Not Eligible for Intensive Induction Therapy

STUDY 2018-068
Phase I/II
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)

OTHER
STUDY 2013-113
Phase II
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia

STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)
For more information on Immunotherapy Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**IMMUNOTHERAPY**

**STUDY 2018-015**

Phase I/II

A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

**RETURN TO TOP**

### Melanoma/Skin Clinical Trials

For more information on Melanoma/Skin Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**ADJUVANT**

**STUDY 2018-095**

Phase III

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

**ADVANCED**

**STUDY 2016-210**

Phase I/II

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

**STUDY 2017-029**

Phase I

An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumors

**STUDY 2017-069**

Phase I/II

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2016-037**

Phase I

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

**STUDY EA6134**

Phase III

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

**STUDY 2013-047**

Phase I

A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

**STUDY 2016-017**

Phase I/II
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

**STUDY 2018-098**
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

**OTHER**

**STUDY 2017-029**
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 in Patients With Advanced Solid Tumours

**STUDY 2017-128**
Phase III
A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma

**STUDY 2016-055**
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY EAY131**
Phase II
Molecular Analysis for Therapy Choice (MATCH)

---

**Neuro-Oncology Clinical Trials**

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

---

**Phase I Clinical Trials**

For more information on Phase 1 Clinical Trials or to refer a patient, please call 313-576-9204 or email Phase1NewPt@karmanos.org. All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure that it is the best treatment option available for them.

**ALL SOLID TUMORS**

**STUDY 2017-111**
Phase I
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

**STUDY 2017-122**
Phase I
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

**STUDY 2018-019**
Phase I
<table>
<thead>
<tr>
<th>Study Number</th>
<th>Study Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018-079</td>
<td>A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2018-156</td>
<td>Phase 1</td>
</tr>
<tr>
<td></td>
<td>A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients with FGFR-positive, Locally Advanced or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>2018-156</td>
<td>STUDY NEW 2018-156</td>
</tr>
<tr>
<td>Phase 1</td>
<td>A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors</td>
</tr>
<tr>
<td>2017-084</td>
<td>STUDY 2017-084</td>
</tr>
<tr>
<td>Phase I</td>
<td>Phase 1b Multi-Indication Study of Anetumab Ravitansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies</td>
</tr>
<tr>
<td>2016-170</td>
<td>STUDY 2016-170</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>A Phase I/IIa, Open-Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy</td>
</tr>
<tr>
<td>2018-104</td>
<td>STUDY 2018-104</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>A Phase I/II, First-in-Human Study of A166 in Patients with Locally Advanced/Metastatic Solid Tumors which are Human Epidermal Growth Factor Receptor 2 (HER2)-Positive who did not Respond or Stopped Responding to Approved Therapies and Patients with HER2 Positive (by ISH or NGS) or Low Expressing (by IHC) Solid Tumors who did not Respond or Stopped Responding to Approved Therapies</td>
</tr>
<tr>
<td>2016-210</td>
<td>STUDY 2016-210</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas</td>
</tr>
<tr>
<td>2018-034</td>
<td>STUDY 2018-034</td>
</tr>
<tr>
<td>Phase I</td>
<td>A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2016-185</td>
<td>STUDY 2016-185</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</td>
</tr>
<tr>
<td>2017-088</td>
<td>STUDY 2017-088</td>
</tr>
<tr>
<td>Phase I</td>
<td>A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2017-052</td>
<td>STUDY 2017-052</td>
</tr>
<tr>
<td>Phase I/II</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2016-157</td>
<td>STUDY 2016-157</td>
</tr>
<tr>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>2018-154</td>
<td>STUDY 2018-154</td>
</tr>
<tr>
<td>Phase I</td>
<td>A Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
</tbody>
</table>
A Phase 1/1b Open-Label Multi-Center to Characterize the Safety and Tolerability of TRQ15-01 in Patients with Relapsed/Refractory Metastatic or Locally-Advanced Solid Tumor or Lymphoma

STUDY 2018-139  
Phase I/II  
Phase I/II Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy

STUDY 2018-158  
Phase I/II  
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors

STUDY 2016-042  
Phase I  
A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone plus Ethinyl Estradiol) in Female Patients with Solid Tumors

STUDY 2016-037  
Phase I  
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2016-075  
Phase I/II  
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

STUDY 2018-066  
Phase I  
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

STUDY 2018-035  
Phase I  
A Phase 1, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-Tumor Activity of FN-1501 Monotherapy in Patients with Advanced Solid Tumors

STUDY 2018-054  
Phase I  
A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2017-101  
Phase I/II  
A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities

TUMOR SPECIFIC  
STUDY 2016-210  
Phase I/II  
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2018-120  
Phase I/II  
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY 2016-037  
Phase I  
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors
STUDY 2013-047
Phase I
A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-018
Phase I
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipiilmumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

GENOMIC TESTING SPECIFIC
STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY NEW 2018-079
Phase I
A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients with FGFR-positive, Locally Advanced or Metastatic Solid Tumors

STUDY 2018-054
Phase I
A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

RETURN TO TOP
Sarcoma Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

RETURN TO TOP

Thoracic Clinical Trials

For more information on Thoracic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ADJUVENT
STUDY NEW 2018-142
Phase III
A Phase III, Double-blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or SELECT IIIB Non-Small Cell Lung Cancer

MAINTENANCE
STUDY NRG-LU002
Phase II/III

STUDY NEW NRG-LU004
Phase I
Phase I Trial of Accelerated or Conventionally Fractionated Radiotherapy Combined With MEDI4736 (Durvalumab) in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1)

STAGE I/II
STUDY 2016-110
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY 2018-074
Phase II
A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin-Ineligible Urothelial Cancer

STUDY NEW 2018-111
Phase III
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted in Adult Patients with Selected Solid Tumors

STAGE III A/B
STUDY 2016-110
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY 2017-152
Phase II
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

STUDY 2018-120
Phase I/II
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

STUDY S1400
Phase II/III
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

STUDY 2018-065
Phase II
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY S1900A
Phase II
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

STUDY NEW 2018-111
Phase III
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

STUDY 2018-060
Phase II
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-074
Phase II
A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin- Ineligible Urothelial Cancer

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

STAGE IV
ALK
STUDY 2018-080
Phase II
Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

**EGFR**

**STUDY 2017-145**  
Phase II  
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

**Other Genetic Marker**

**STUDY S1400**  
Phase II/III  
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

**STUDY 2017-145**  
Phase II  
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

**STUDY S1900A**  
Phase II  
A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

**STUDY 2018-065**  
Phase II  
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors

**STUDY 2018-120**  
Phase I/II  
An Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination with Pembrolizumab in Patients with Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma

**STUDY 2017-111**  
Phase I  
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

**STUDY 2016-017**  
Phase I/II  
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

**STUDY 2016-055**  
Phase I  
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2014-002**  
Phase II  
A Study to Assess the Ability to Initiate Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens

**STUDY 2016-037**  
Phase I  
A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
STUDY 2018-060
Phase II
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2017-129
NA
Improving Treatment Cost Discussions between Cancer Patients and their Oncologists: Feasibility and Utilization of an Application-based Question Prompt List

STUDY 2018-074
Phase II
A Phase 2, Open-Label Study to Evaluate Safety and Clinical Activity of Avelumab (Bavencio) in Combination with Axitinib (Inlyta) in Patients with Advanced or Metastatic Previously Treated Non-Small Cell Lung Cancer or Treatment Naive Cisplatin- Ineligible Urothelial Cancer

STUDY 2018-053
Phase III
METIS: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)

STUDY 2018-098
Phase I/II
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Anti-Tumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients with Selected Solid Tumors

RECURRENT
ALK
STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

EGFR
STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

Other Genetic Marker
STUDY 2018-015
Phase I/II
A Phase 1b/2 Study to Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Or Metastatic Solid Tumors

STUDY 2018-065
Phase II
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or N-145) in Patients with Solid Tumors
MESOTHELIOMA
STUDY 2018-105
Phase II
Study of Nivolumab and Ramucirumab for Patients with Previously-Treated Mesothelioma

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2018-081
Phase I
A Phase I Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-e4 (KP-673) in Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor (EGFR) Mutations

STUDY 2018-171
Phase II
A Phase II, Open Label, Multi-Dose Study of 89ZR-DF-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients with Metastatic Solid Tumors

STUDY 2016-116
Phase II
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipinlimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours